Abstract
Keywords: inclusion body myositis; sporadic inclusion body myositis (sIBM) - common myopathy in Caucasians over 50 years of age; epidemiology and genetic susceptibility; genetic susceptibility, linked to HLA-DR3 and 8.1 MHC ancestral haplotype (AH) in West Australian cohort; serum CK level - normal or mildly elevated (up to 10 times normal); no therapy currently - for stopping disease progression; intravenous immunoglobulin therapy (IVIG) - short-term benefit in selected cases; glucocorticoids and cytotoxic agents
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
